Clinical Trials Browser

Phase 2 × Waldenstrom Macroglobulinemia × venetoclax × Clear all

NCT04840602 2026-03-18

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07387471 2026-03-16

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT05099471 2025-11-28

VIWA-1

Phase 2 Recruiting

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT07231952 2025-11-17

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT04273139 2025-07-30

Ibrutinib + Venetoclax in Untreated WM

Phase 2 Active not recruiting

45 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT05734495 2025-05-11

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT02677324 2022-05-11

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

Phase 2 Completed

33 enrolled 15 charts

Waldenstrom Macroglobulinemia